Researchers from AIMMS (VU), MCBI (AUMC) and Abera Bioscience publish jointly on novel vaccination technologies
The articles report on two innovative vaccination platforms that drive cellular immune responses
10/14/2019 | 4:27 PM
Over the years vaccines have prevented countless cases of disease and saved millions of lives. Moreover, there is a growing trend to develop vaccines for active immune therapy of already existing diseases, including cancer. In a collaborative effort that includes the groups of Yvette van Kooyk (Molecular Cell Biology and Immunology, AUMC), Joen Luirink (Molecular Microbiology, AIMMS) and vaccine start-up Abera Bioscience, two novel vaccination platforms based on bacterial outer membrane vesicles (OMVs) and inclusion bodies (IBs) were tested. It was shown that both platforms drive strong induction of T cell-based responses, of interest for various vaccination strategies. The results of the studies are now published in Acta Biomaterialia and Cellular & Molecular Immunology.